All News

woman-1284353_640.jpg

Babies! Safety and Outcomes Data on Pregnancies

Kathryn H. Dao, M.D.

EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years.

Read Article
RNL22 RA Best Management

RNL 2022: Rheumatoid Arthritis - Best Management

Jack Cush, MD

This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:

Read Article
coronavirus,COVID,Mask,red

Increasing Corticosteroid Use in Non-Hospitalized COVID-19

Jack Cush, MD

JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.

Read Article
renal.genes_.jpg

Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?

Jack Cush, MD

SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects. Maybe these agents should be considered and studied in lupus nephritis and ANCA- associated vasculitis.

Read Article
RheumNow Podcast square

What is JAKne? (5.6.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.

Read Article
myositis.jpg

BSR Guideline on Idiopathic Inflammatory Myopathy

Jack Cush, MD

The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.

Read Article
Gout pills injection

Allopurinol Use Does Not Increase Mortality in Gout with Chronic Kidney Disease

Jack Cush, MD

A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD

Read Article
More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0.26) with no evidence of adrenal insufficiency. Can successfully withdraw long term steroids! @RheumNow #EULAR2022 OP0270 https://t.co/IV9iJLY22v https://t.co/ZXdwxlXorK

Links:

Richard Conway RichardPAConway ( View Tweet)
In case there was doubt: - steroid toxicity is real in GCA - giving steroid-sparing therapies (TCZ, MTX) early makes a difference just something to not forget when your next new GCA patient rolls in the door? POS0805 #EULAR2022 @RheumNow https://t.co/2wGV3M8wZD
David Liew drdavidliew ( View Tweet)
Boers et al. GLORIA trial of long term 5mg pred in RA. Titled as "favourable balance of benefit and harm". I cannot agree. 24% increase adverse events, NNH 9, for DAS28 0.37 better at 1 year, and really no difference after that. @RheumNow #EULAR2022 OP0263 https://t.co/eO4f1CjH5q https://t.co/VyyZm1QvYy

Links:

Richard Conway RichardPAConway ( View Tweet)
Long-term low-dose steroids for RA: can it be weaned? Weaning after 2y of blinded add-on in RA: either PNL 5mg/d or placebo No substantial evidence of adrenal insufficiency - symptoms same - cortisol/ACTH same It's never too late to wean the pred! OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb
David Liew drdavidliew ( View Tweet)
Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
Richard Conway RichardPAConway ( View Tweet)
Unizony et al. Case series of tocilizumab + 8 weeks steroid in GCA. 30 patients, 50% new 50% relapsing. 77% in sustained remission at week 52! No vision loss. Exciting, needs an RCT @RheumNow #EULAR2022 OP0185 https://t.co/ohBYIWYxBC https://t.co/fsn4x17Hwv

Links:

Richard Conway RichardPAConway ( View Tweet)
#Behcets. If topical oracort / steroids don’t work for Mucosal ulcers consider topical #tacrolimus https://t.co/7ZiLfdwZoP

Links:

Janet Pope Janetbirdope ( View Tweet)

Continue with PJP prophylaxis during the 6 months of induction Rx and until B cells repleted and if prednisone > = 20 mg/day #EULAR2022 AAV reccs @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

#EULAR2022 TREAT-EARLIER OP0700 Arthralgia + subclinical inflammation in MRI without RA, treated with MTX + depo steroid injection ▶️In High risk patients, delayed development of synovitis, but does not prevent in long-term ▶️Reduction in disease burden on MTX Rx @RheumNow https://t.co/SKlqMQQTui
Eric Dein ericdeinmd ( View Tweet)
ACR21: conditionally recommends against steroids with starting csDMARD #EULAR2022 recommends with rapid GC dose reduction and discontinuation Which is better recommendation? @RheumNow

Eric Dein ericdeinmd ( View Tweet)

And now the paper that no one can find even if they are looking for it. On the relationship between disease activity and glucocorticoid disease. https://t.co/aT8I0jwQOJ @rheum_covid @ARD_BMJ https://t.co/7ntGLPdypJ

Links:

The COVID-19 Global Rheumatology Alliance rheum_covid ( View Tweet)
"I think we can get rid of maintenance prednisone in nonrenal lupus" (but not in renal lupus) "...prednisone contributes to some organ damage (but not renal)" Organ damage is multifactorial -traditional risk factors, disease activity & steroids - Dr. Michelle Petri #UTSWSLE2022 https://t.co/N9NMPgtPEn
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 71 adult-onset Still’s disease pts Rx 1st w/ High-dose glucocorticoids shows 41% failed to respond (poor outcome) by week4 w/ WBC as best predictor. If WBC < 13K 60% responded; if ≥13K only 23.5% https://t.co/tMNDgoqP14 https://t.co/xJrIEUU6iK

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×